Email Sales

Email Sales

Need product support? Please visit our Customer Support page.

×

 

 

 

Back to Insights & Analysis

Chasing the Next Biotech Unicorn

How private equity sets to thrive in the biotech boom in Hong Kong

New listing rules in Hong Kong for biotech and the healthcare reform in China are propelling capital raising activities in the region. Rocketed valuation in the biotech sector drives interest from private equity investments, who demand swift investment cycle with a clear profit-making path for going public. The importance of rigorous and timely pre-investment screening and due diligence process is at an all-time high.

Download this whitepaper to examine the potential opportunities and headwinds in the biotech state-of-play, as well as factors that would drive deal success.

View Premium Content

Sign up once and access our entire library of premium content—white papers, webinars and reports—at any time.

All fields required*

 

 

I agree

This site uses cookies to offer you a better experience. For more information, view our privacy policy.